Novartis AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novartis AG with three other
companies in this sector in the United States:
sales of $48.85 billion
of which 44%
was Operating Segment-Global Established Pha),
Merck & Co. , Inc.
of which 88%
was Merck Pharmaceutical), and
of which 85%
Novartis AG reported sales of $50.36 billion
December of 2015.
decrease of 6.1%
versus 2014, when the company's sales were $53.63 billion.
The sales level in 2015 was fairly close to the level five years ago: in 2010, Novartis AG had sales
of $50.89 billion.
Contributing to the drop in overall sales was the 10.1% decline
in Alcon, from $10.91 billion to $9.81 billion.
There were also decreases in sales in
Pharmaceuticals (down 6.8% to $30.44 billion)
Sandoz (down 7.1% to $9.16 billion)